Rhythm Biosciences Says Initial Testing Validates Efficacy of Second-Generation Bowel Cancer Diagnostic Kit

MT Newswires Live

Oct 07, 2024

Rhythm Biosciences (ASX:RHY) said initial testing validated the efficacy of its second-generation ColoSTAT diagnostic kit for bowel cancer, according to a Monday filing with the Australian bourse.

Following a serum sample test, the second-generation kit recorded a 0.805 performance value, compared with 0.784 for the first-generation test kit.

Over the coming weeks, the medical diagnostics company will work with contract manufacturing organization, Quansys, to produce the beta version of the assay to develop the commercial version of the algorithm and further verification and validation, the filing said.

Shares of Rhythm Biosciences surged almost 45% at market close on Monday.

Price (AUD): $0.11, Change: $+0.034, Percent Change: +44.74%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2473112864"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2473112864\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2473112864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-07 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2473112864","market":"fut","top_or_hot":-1,"title":"Rhythm Biosciences Says Initial Testing Validates Efficacy of Second-Generation Bowel Cancer Diagnostic Kit","media":"MT Newswires Live","content":"<html><body><p> Rhythm Biosciences (ASX:RHY) said initial testing validated the efficacy of its second-generation ColoSTAT diagnostic kit for bowel cancer, according to a Monday filing with the Australian bourse.</p><p>Following a serum sample test, the second-generation kit recorded a 0.805 performance value, compared with 0.784 for the first-generation test kit.</p><p>Over the coming weeks, the medical diagnostics company will work with contract manufacturing organization, Quansys, to produce the beta version of the assay to develop the commercial version of the algorithm and further verification and validation, the filing said.</p><p>Shares of Rhythm Biosciences surged almost 45% at market close on Monday.</p><p>Price (AUD): $0.11, Change: $+0.034, Percent Change: +44.74%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rhythm Biosciences Says Initial Testing Validates Efficacy of Second-Generation Bowel Cancer Diagnostic Kit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRhythm Biosciences Says Initial Testing Validates Efficacy of Second-Generation Bowel Cancer Diagnostic Kit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-07 14:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Rhythm Biosciences (ASX:RHY) said initial testing validated the efficacy of its second-generation ColoSTAT diagnostic kit for bowel cancer, according to a Monday filing with the Australian bourse.</p><p>Following a serum sample test, the second-generation kit recorded a 0.805 performance value, compared with 0.784 for the first-generation test kit.</p><p>Over the coming weeks, the medical diagnostics company will work with contract manufacturing organization, Quansys, to produce the beta version of the assay to develop the commercial version of the algorithm and further verification and validation, the filing said.</p><p>Shares of Rhythm Biosciences surged almost 45% at market close on Monday.</p><p>Price (AUD): $0.11, Change: $+0.034, Percent Change: +44.74%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999003826.SGD","symbol_name":"日兴资管新加坡股息基金 SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2473112864","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473112864","pubTimestamp":1728283952,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Rhythm Biosciences  said initial testing validated the efficacy of its second-generation ColoSTAT diagnostic kit for bowel cancer, according to a Monday filing with the Australian bourse.Following a serum sample test, the second-generation kit recorded a 0.805 performance value, compared with 0.784 for the first-generation test kit.Over the coming weeks, the medical diagnostics company will work with contract manufacturing organization, Quansys, to produce the beta version of the assay to develop the commercial version of the algorithm and further verification and validation, the filing said.Shares of Rhythm Biosciences surged almost 45% at market close on Monday.Price : $0.11, Change: $+0.034, Percent Change: +44.74%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","BK7124":"保健护理服务","SG9999001069.SGD":"UOB UNITED ASIA PACIFIC GROWTH (SGD) ACC","A7RU.SI":"吉宝基础设施信托","BK6501":"化工股","SG9999003461.SGD":"United Asia Pacific Infrastructure SGD","BK4125":"广播","BK6031":"特种化学制品","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD","BK6102":"燃气公用事业","RHY.AU":"RHYTHM BIOSCIENCES LTD","SG9999002950.SGD":"United Asian Growth Opportunities SGD"},"translate_title":"Rhythm Biosciences表示初步测试验证了第二代肠癌诊断试剂盒的功效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A7RU.SI":1,"AUD":1,"RHY.AU":0.9},"content_text":"Rhythm Biosciences (ASX:RHY) said initial testing validated the efficacy of its second-generation ColoSTAT diagnostic kit for bowel cancer, according to a Monday filing with the Australian bourse.Following a serum sample test, the second-generation kit recorded a 0.805 performance value, compared with 0.784 for the first-generation test kit.Over the coming weeks, the medical diagnostics company will work with contract manufacturing organization, Quansys, to produce the beta version of the assay to develop the commercial version of the algorithm and further verification and validation, the filing said.Shares of Rhythm Biosciences surged almost 45% at market close on Monday.Price (AUD): $0.11, Change: $+0.034, Percent Change: +44.74%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}